儿童起病系统性红斑狼疮增殖性狼疮肾炎激素给药国际共识
该国际共识采用共识形成方法制定儿童起病系统性红斑狼疮(SLE)合并增殖性狼疮肾炎(LN)的标准化激素给药方案(SSR)。基于影响激素剂量的参数和患者概况评级,开发了SSR并在肾脏活检后长达6个月的患者概况中得到验证,口服和静脉激素剂量均达到共识。SSR旨在用于临床护理和临床试验中标准化激素剂量。
要点
- 影响激素剂量的参数包括蛋白尿程度、eGFR、肾脏及肾外疾病活动变化和肾活检后时间。
- SSR基于103名评级者的5056份患者概况评级开发,并在60名评级者的1838份评级中验证。
- SSR推荐口服和静脉激素剂量在肾活检后长达6个月内获得共识验证。
核心结论
- SSR代表了儿童起病SLE合并增殖性LN激素给药的国际共识,预期用于临床护理和临床试验中标准化激素剂量。
研究设计与样本
- 采用共识形成方法,分6步开发标准化激素给药方案(SSR),包括参数识别、患者概况生成、医生评级、SSR开发、焦点小组细化及验证。
- 开发阶段纳入103名评级者对5056份患者概况的评级,验证阶段纳入60名评级者对1838份患者概况的评级。
主要发现
- 蛋白尿程度、估算肾小球滤过率(eGFR)、肾脏和肾外疾病活动变化及肾活检后时间影响激素剂量。
- 基于患者概况评级和肾脏/肾外病程定义,制定了SSR的激素给药规则。
- SSR在肾活检后长达6个月内的验证中,口服和静脉激素剂量达到共识(共识水平设为80%)。
关键数值与推荐
- 患者概况裁定基于肾脏和肾外疾病病程的多数评级,共识水平设定为80%。
- 验证阶段中60名评级者对1838份患者概况的评级达到共识,支持SSR推荐的口服和静脉激素剂量。
临床怎么用
- SSR可用于儿童起病SLE合并增殖性LN的临床护理,以标准化激素剂量。
- SSR预期在临床试验中用于标准化激素剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop a standardized steroid dosing regimen (SSR) for physicians treating childhood-onset systemic lupus erythematosus (SLE) complicated by lupus nephritis (LN), using consensus formation methodology. METHODS: Parameters influencing corticosteroid (CS) dosing were identified (step 1). Data from children with proliferative LN were used to generate patient profiles (step 2). Physicians rated changes in renal and extrarenal childhood-onset SLE activity between 2 consecutive visits and proposed CS dosing (step 3). The SSR was developed using patient profile ratings (step 4), with refinements achieved in a physician focus group (step 5). A second type of patient profile describing the course of childhood-onset SLE for ≥4 months since kidney biopsy was rated to validate the SSR-recommended oral and intravenous (IV) CS dosages (step 6). Patient profile adjudication was based on majority ratings for both renal and extrarenal disease courses, and consensus level was set at 80%. RESULTS: Degree of proteinuria, estimated glomerular filtration rate, changes in renal and extrarenal disease activity, and time since kidney biopsy influenced CS dosing (steps 1 and 2). Considering these parameters in 5,056 patient profile ratings from 103 raters, and renal and extrarenal course definitions, CS dosing rules of the SSR were developed (steps 3-5). Validation of the SSR for up to 6 months post-kidney biopsy was achieved with 1,838 patient profile ratings from 60 raters who achieved consensus for oral and IV CS dosage in accordance with the SSR (step 6). CONCLUSION: The SSR represents an international consensus on CS dosing for use in patients with childhood-onset SLE and proliferative LN. The SSR is anticipated to be used for clinical care and to standardize CS dosage during clinical trials.
引用
- Chalhoub NE, Wenderfer SE, Levy DM, et al. International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis. Arthritis Rheumatol. 2022. PMID: 34279063. doi:10.1002/art.41930
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。